Background: Linear scars, resulting from surgical incisions or traumatic injuries, can pose both aesthetic and functional dilemmas. Ablative fractional CO₂ laser (AFCL) therapy has been recognized for its ability to enhance the appearance and flexibility of scars; however, the ideal timing for such treatments remains a subject of debate.Aims: This study retrospectively evaluates the effectiveness of AFCL in treating linear atrophic and hypertrophic scars, with a focus on identifying the optimal timing to achieve the best possible outcomes.Methods: Patients who underwent treatment for linear scars using AFCL at our hospital between January 2022 and July 2024 were included in the study. Participants were categorized into two groups: those with atrophic scars and those with hypertrophic scars. Hypertrophic scars were assessed using the Vancouver Scar Scale (VSS), whereas atrophic scars were evaluated with the Scar Cosmesis Assessment and Rating (SCAR) scale. Furthermore, considering the timing of scar formation—with a six‐month period as the threshold—two subgroups were categorized as early treatment and late treatment. The disparities in scar improvement rates were then computed and subjected to analysis.Results: Among 55 patients, 31 had atrophic scars and 24 had hypertrophic scars. AFCL treatment significantly improved clinical scores in both groups. The SCAR score for atrophic scars decreased from 6.50 (SD 1.31) to 4.92 (SD 1.71) (p < 0.001), and the VSS score for hypertrophic scars decreased from 6.02 (SD 0.46) to 2.73 (SD 0.39) (p < 0.001). The early‐treatment subgroup showed a 35.38% (SD 24.54%) improvement in atrophic scars, significantly higher than the 12.53% (SD 25.65%) in the late‐treatment subgroup (p = 0.018). No significant timing effect was found for hypertrophic scars (p = 0.764).Conclusion: AFCL is an effective treatment for linear scars. Early intervention, specifically within the first 6 months, leads to superior outcomes for atrophic scars. In contrast, the timing of treatment is less critical for hypertrophic scars.Trial Registration: Chinese clinical trial registry: Registration no. ChiCTR2400092038
Background: Conventional diagnostic methods for onychomycosis possess disadvantages related to limited sensitivity, extended turnaround times and strong reliance on operator expertise. Objectives: To develop a molecular assay with high sensitivity and specificity for rapid detection of multiple fungal pathogens in nail specimens. Methods: A multi‐tube recombinase polymerase amplification (RPA) assay with fluorescent signal detection was developed, targeting pan‐fungal, Trichophyton rubrum , T. interdigitale , pan‐ Candida , Candida albicans , pan‐ Trichosporon and pan‐ Aspergillus . The analytical sensitivity and specificity of the assay were evaluated using fungal strains, and its performance was assessed in 81 clinical nail specimens in parallel with calcofluor white fluorescence microscopy and fungal culture. Results: The multi‐tube RPA assay demonstrated a detection limit of 1 pg of genomic DNA for all targets, with a turnaround time of < 70 min. In the evaluation of 81 clinical nail specimens, Bayesian latent class analysis estimated sensitivities of 86.0% for multi‐tube RPA, 67.0% for fungal culture and 77.0% for microscopy, with corresponding specificities of 85.0%, 89.0% and 87.0%. The positive and negative predictive values were 92.0% and 72.0% for multi‐tube RPA, 93.0% and 55.0% for fungal culture, and 93.0% and 66.0% for microscopy. Conclusion: Compared with fungal culture and microscopy, the multi‐tube RPA assay demonstrated superior sensitivity while maintaining good specificity, facilitating the identification of fungal pathogens at the species level in nail specimens. Its operational simplicity, enhanced diagnostic performance and reduced processing times make it a promising alternative for the mycological diagnosis of onychomycosis.
Background: Candidozyma auris , also known as Candida auris , is an emerging multidrug-resistant fungal pathogen that represents a major global health concern; however, its risk factors and antifungal resistance patterns in bloodstream infections (BSIs) in Southern China remain insufficiently characterized. Therefore, this study aimed to identify risk factors and antifungal resistance patterns associated with C. auris BSIs. Methods: A retrospective analysis was performed on 137 patients with candidemia at a large tertiary hospital in Southern China between October 2023 and September 2025. Least absolute shrinkage and selection operator regression followed by multivariate logistic regression was used to identify independent risk factors, and antifungal susceptibility testing was performed. Minimum inhibitory concentrations were determined and interpreted in accordance with the Clinical and Laboratory Standards Institute M27-A3 guideline. Results: C. auris was identified as the predominant pathogen, accounting for 39.4% (54/137) of candidemia cases, indicating an evident regional predominance and substantial burden. Independent risk factors included hypertension (OR = 6.283, 95% CI: 2.466–17.719), mechanical ventilation (OR = 4.329, 95% CI: 1.585–12.980), use of two or more antibiotics at infection onset (OR = 5.991, 95% CI: 2.349–16.686), and glucocorticoid therapy (OR = 3.100, 95% CI: 1.196–8.509). The 30-day mortality rate associated with C. auris infection was 18.5%. Lower C-reactive protein levels were independently associated with C. auris BSIs (OR = 0.987, 95% CI: 0.978–0.995), potentially reflecting a distinct host inflammatory response rather than representing a predisposing risk factor. Antifungal susceptibility testing revealed universal resistance to fluconazole (100%), while susceptibility to echinocandins was retained. Conclusions: This study identified C. auris as an emerging leading cause of candidemia in this region, characterized by different clinical risk factors and high antifungal resistance, highlighting the importance of early identification and targeted infection control strategies.